Notice of Results, Analyst & Investor Presentation

Thalia Therapeutics

19/09/2025 07:00

RNS Number : 9469Z

N4 Pharma PLC

19 September 2025

 

 

 

 

19 September 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Notice of Results

Analyst Briefing and Investor Presentation

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, will announce its unaudited interim results for the six months ended 30 June 2025 on Thursday, 25 September 2025 and hold the following analyst briefing and investor presentation.

 

Analyst briefing

 

An online briefing for analysts will be hosted by Nigel Theobald, Chief Executive Officer, at 9.30 am on Thursday, 25 September 2025, to review the interim results. Analysts wishing to attend should contact Sarah Hollins at Northstar Communications at sarah@northstarcommunications.co.uk.

 

Investor presentation

 

An investor presentation to cover the interim results will be held at 2.00 pm on Thursday, 25 September 2025.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 am on Wednesday, 24 September 2025 or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:

https://www.investormeetcompany.com/n4-pharma-plc/register-investor

 

Investors who already follow N4 Pharma plc on the Investor Meet Company platform will automatically be invited.

 

- Ends -

For more information please contact:

 

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:investors.n4pharma.com
https://n4pharma.com/link/y05doe
SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896

 

About N4 Pharma

 

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NORSFLFIAEISEIU